Related Experiment Video
Updated: Aug 9, 2025
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
Antagonism between Prdm16 and Smad4 specifies the trajectory and progression of pancreatic cancer
Eric Hurwitz1, Parash Parajuli1, Seval Ozkan2
1Department of Biochemistry and Molecular Biology, Massey Cancer Center, Virginia Commonwealth University , Richmond, VA, USA.
Abstract:
The transcription factor Prdm16 functions as a potent suppressor of transforming growth factor-beta (TGF-β) signaling, whose inactivation is deemed essential to the progression of pancreatic ductal adenocarcinoma (PDAC). Using the KrasG12D-based mouse model of human PDAC, we surprisingly found that ablating Prdm16 did not block but instead accelerated PDAC formation and progression, suggesting that Prdm16 might function as a tumor suppressor in this malignancy. Subsequent genetic experiments showed that ablating Prdm16 along with Smad4 resulted in a shift from a well-differentiated and confined neoplasm to a highly aggressive and metastatic disease, which was associated with a striking deviation in the trajectory of the premalignant lesions. Mechanistically, we found that Smad4 interacted with and recruited Prdm16 to repress its own expression, therefore pinpointing a model in which Prdm16 functions downstream of Smad4 to constrain the PDAC malignant phenotype. Collectively, these findings unveil an unprecedented antagonistic interaction between the tumor suppressors Smad4 and Prdm16 that functions to restrict PDAC progression and metastasis.
Insights
Prdm16 unexpectedly accelerates pancreatic cancer when removed, revealing its role as a tumor suppressor. Its interaction with Smad4 restrains pancreatic ductal adenocarcinoma (PDAC) progression and metastasis.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Transforming growth factor-beta (TGF-β) signaling is crucial in cancer, with its suppression by Prdm16 implicated in pancreatic ductal adenocarcinoma (PDAC) progression.
- Inactivation of TGF-β signaling is considered essential for PDAC development.
Purpose of the Study:
- To investigate the role of Prdm16 in PDAC formation and progression.
- To elucidate the mechanism underlying Prdm16's function in PDAC.
Main Methods:
- Utilized a KrasG12D-based mouse model for PDAC.
- Performed genetic ablation of Prdm16 and Smad4.
- Analyzed the impact on PDAC formation, progression, and metastatic potential.
Main Results:
- Ablation of Prdm16 accelerated PDAC formation and progression, contrary to expectations.
- Simultaneous ablation of Prdm16 and Smad4 led to highly aggressive and metastatic disease.
- Prdm16 was found to interact with Smad4 to repress Smad4 expression, acting downstream of Smad4.
Conclusions:
- Prdm16 functions as a tumor suppressor in PDAC, not a promoter.
- An antagonistic interaction between Smad4 and Prdm16 restricts PDAC progression and metastasis.
- These findings reveal a novel mechanism regulating PDAC malignancy.
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
02:23Abnormal Proliferation
01:16TGF - β Signaling Pathway
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
01:19Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...